Welcome to our dedicated page for Ludwig Enter news (Ticker: LUDG), a resource for investors and traders seeking the latest updates and insights on Ludwig Enter stock.
Ludwig Enterprises, Inc. (LUDG) generates frequent news as it advances its mRNA- and AI-based diagnostics platform and prepares its Revealia™ cancer screening products for broader use. Company updates focus on scientific milestones, clinical research presentations, product development progress, corporate initiatives, and leadership changes, giving investors and observers insight into how its genomics-based strategy is evolving.
Recent press releases highlight the company’s work on non-invasive breast cancer screening using buccal (cheek) cell mRNA combined with machine learning. Ludwig Enterprises has announced abstracts accepted for publication in the Journal of Clinical Oncology and posted on the American Society of Clinical Oncology (ASCO) website, detailing how panels of mRNA biomarkers and algorithms can generate a breast cancer detection signal from cheek swab samples. Other news has covered the introduction and advanced development of Revealia Breast™, a cheek-swab-based breast cancer screening test designed to establish a personalized inflammatory index and risk score.
Beyond clinical data, Ludwig Enterprises’ news flow includes updates on assay optimization and third-party PCR validation for its Revealia™ program, as well as the filing of a provisional patent for a cancer detection method based on a six-mRNA gene combination. The company has also reported the acquisition of intellectual property for an mRNA Neuro Panel and Serotonin Assay, which it links to potential applications in neuroinflammatory and neurological conditions.
Corporate and capital markets developments also appear in LUDG news, including plans to change the corporate name to Revealia, Inc. or Revealia Diagnostics, Inc., intentions to pursue higher-tier listings, and announcements of new executive appointments. For readers tracking LUDG, this news page offers a centralized view of the company’s scientific progress, product pipeline, and strategic direction over time.
Ludwig Enterprises Inc. (OTC PINK:LUDG) announced the successful completion of its first round of new project funding, receiving $200,000 in private equity. The company has divested from its financial services unit to focus on technology and health-related projects. On May 18, 2022, Anne Blackstone was appointed CEO and sole director of mRNAforLife, Inc., a subsidiary aimed at health field acquisitions. Following Jean Cherubin's retirement on June 1, 2022, Blackstone also became CEO and Director of Ludwig Enterprises, indicating a strategic shift back to core business interests.
Ludwig Enterprises (OTC PINK:LUDG) announced a resolution to call $80,471.67 of convertible notes, leading to the issuance of 8,047,167 new common shares at $0.01 per share. The company is in the process of unwinding its relationship with Direct Mortgage Investors, resulting in an asset loss exceeding $600,000. Ludwig aims to focus on its core operations in technology and health-related fields. Additionally, it is monitoring third-party litigation related to ownership of 28 million shares.
Ludwig Enterprises Inc. has decided to unwind its subsidiary Direct Mortgage Investors, Inc., effective immediately. This move aims to refocus on technology and health-related sectors after Direct operated as a wholly owned subsidiary since 2019. Although Ludwig anticipates a short-term asset loss exceeding $600,000, the Board believes this strategic decision will enhance long-term shareholder value. Additionally, a third-party litigation regarding approximately 28 million Ludwig shares is being monitored, although neither party is involved in the case.